A couple of comments –today’s blog (below) and yesterday’s blog both point out potential concerns with proton pump inhibitors (PPIs). There is a danger that when publications emphasize the potential consequences of PPI use (including NPR’s recent piece on kidney disease and PPIs) that physicians and families will overlook the value of these medications.
With regard to the benefits of PPIs, there are a large number of studies supporting the effectiveness of PPIs for various GI conditions. As a result, there is little being published on drug effectiveness at this time. On a daily basis, these medications prevent a great deal of suffering, heal esophagitis, heal ulcers and contribute to improved health. If one looks only at the negative side of the ledger, this could create harm.
My personal belief is that when PPIs are used, that it is important to consider both the advantages and the disadvantages. If the benefits are unclear, this increases the necessity of evaluating the risks, especially in vulnerable populations. In addition, when the benefits are unclear, determining the length of therapy and/or performing appropriate diagnostic workup becomes essential.
Also, for pediatric gastroenterologists reading this blog, it is important to realize that my blog’s following is tiny in comparison to the circulation of the Journal of Pediatrics and news organizations like NPR. Therefore, we need to engage our pediatrician/family medicine colleagues to help make sure that PPIs are used effectively. I am looking forward to the January 26 NASPGHAN webinar on this topic.
The degree to which proton pump inhibitors (PPIs) affect the gut microbiome is unclear. A recent study of 12 healthy volunteers (DE Freedberg et al. Gastroenterol 2015; 149: 883-85, Clearing Out My Desk | gutsandgrowth) indicated that this was not much; however, an even more recent study (F Imhann et al. Gut 2015 December 9 (Gut doi:10.1136/gutjnl-2015-310376)) suggests otherwise (abstract below) -their conclusion: “On a population level, the effects of PPI are more prominent than the effects of antibiotics or other commonly used drugs.”
BACKGROUND AND AIMS: Proton pump inhibitors (PPIs) are among the top 10 most widely used drugs in the world. PPI use has been associated with an increased risk of enteric infections, most notably Clostridium difficile. The gut microbiome plays an important role in enteric infections, by resisting or promoting colonisation by pathogens. In this study, we investigated the influence of PPI use on the gut microbiome.
METHODS: The gut microbiome composition of 1815 individuals, spanning three cohorts, was assessed by tag sequencing of the 16S rRNA gene. The difference in microbiota composition in PPI users versus non-users was analysed separately in each cohort, followed by a meta-analysis.
RESULTS: 211 of the participants were using PPIs at the moment of stool sampling. PPI use is associated with a significant decrease in Shannon’s diversity and with changes in 20% of the bacterial taxa (false discovery rate <0.05). Multiple oral bacteria were over-represented in the faecal microbiome of PPI-users, including the genus Rothia (p=9.8×10(-38)). In PPI users we observed a significant increase in bacteria: genera Enterococcus, Streptococcus, Staphylococcus and the potentially pathogenic species Escherichia coli.
CONCLUSIONS: The differences between PPI users and non-users observed in this study are consistently associated with changes towards a less healthy gut microbiome. These differences are in line with known changes that predispose to C. difficile infections and can potentially explain the increased risk of enteric infections in PPI users. On a population level, the effects of PPI are more prominent than the effects of antibiotics or other commonly used drugs.
My take: It is likely that the effects on the microbiome are even more notable in infants/younger children; in neonates, the changes in the microbiome could increase the risk of serious diseases like necrotizing enterocolitis.
Related blog posts:
- How Proton Pump Inhibitors Can Cause Infections | gutsandgrowth
- Avoid ranitidine (acid suppression) in neonates | gutsandgrowth
- PPI Side Effects: “Dissecting the Evidence” | gutsandgrowth
- No Effect of Proton Pump Inhibitors and Irritability… | gutsandgrowth
- How Histamine-2 Receptor Blockers May Cause Problems for Preemie